[et_pb_section fb_built=”1″ _builder_version=”4.5.3″][et_pb_row _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.5.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” hover_enabled=”0″] We are delighted to announce that Academic in Residence Kostas Tzelepis has been awarded a John Goldman Fellowship from Leukaemia UK to develop and characterize new drugs against the RNA methyltransferase METTL3, which he has previously uncovered as a …

We are delighted to announce that Kathryn Lilley, Director of the Cambridge Centre for Proteomics, is among 63 leading scientists who have been awarded EMBO membership today – elected on the basis of their scientific excellence and pioneering research.  “The new Members have contributed to the success of research in the life sciences in Europe …

Start Codon, the new healthcare accelerator based in the Milner Therapeutics Institute, today announced the first cohort of four companies who were enrolled in the programme this February and will debut at the Milner Symposium event this Friday June 26th and ONHelix on July 14th. Dr Jason Mellad, Co-founder and CEO at Start Codon, said: …

We are delighted to announce that Eisai have joined the Milner Therapeutics Consortium, which now includes 8 pharma partners. Eisai is a leading global research and development-based pharmaceutical company headquartered in Japan. Eisai’s corporate mission is defined as “giving first thought to patients and their families and to increasing the benefits health care provides,” also …

[et_pb_section fb_built=”1″ admin_label=”section” _builder_version=”3.22″][et_pb_row admin_label=”row” _builder_version=”3.25″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text admin_label=”Text” _builder_version=”4.5.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat”] The Jeffrey Cheah Biomedical Centre illuminated blue tonight, to honour the incredible work of our NHS. Milner Institute Director Professor Tony Kouzarides said “On behalf of scientists in Cambridge and throughout the UK, we thank NHS staff …

We have been busy adapting plans for the coming months, and are pleased to announce that our Milner seminars are moving online. The first talk is from Mathew Garnett, and we hope you will join us online for this!  Dr Mathew Garnett (Wellcome Sanger Institute) Functional genomics approaches to guide cancer discovery This talk will …

Thank you to the numerous Milner affiliated companies who have been in contact to offer support  to the University and NHS at this time. Help tackle COVID-19 through research collaborations, by donating equipment or funding research The University of Cambridge is co-ordinating activities to address COVID-19, including: Establishing research collaborations with other research institutions, industrial and charity partners …

As part of the response to COVID-19 at the University of Cambridge, the Milner Therapeutics Institute will be closed for non-essential business from Friday March 20th until further notice. Events planned for March and April, including the Milner seminar series, have been postponed. We are continuing to plan for the Milner Therapeutics Symposium in June, …

We are delighted that Dr Konstantinos Tzelepis has moved into the Milner Centre for Pathway Analysis as a new Academic in Residence. He brings significant expertise in the identification and characterisation of novel therapeutic targets using a wide range of applied functional genetics including sophisticated CRISPR-Cas9 screening platforms, which will be vital as we expand …